Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005)
Journal article published in 2011 by
D. S. Hong,
M. E. Cabanillas,
J. Wheler,
A. Naing,
A. M. Tsimberidou,
L. Ye,
S. G. Waguespack 
,
M. Hernandez,
A. K. El Naggar,
S. Bidyasar,
N. L. Busaidy,
J. Wright,
S. I. Sherman,
R. Kurzrock
,
M. Hernandez,
A. K. El Naggar,
S. Bidyasar,
N. L. Busaidy,
J. Wright,
S. I. Sherman,
R. Kurzrock
